Dr Yukata Niihara felicitated by Minister of State, Arun Halder for developing FDA- approved drug ENDARI to fight SCD

By ANI | Published: December 16, 2022 05:42 PM2022-12-16T17:42:10+5:302022-12-16T23:15:12+5:30

Dr Yukata Niihara, e CEO and Chair of Emmaus life sciences Inc. USA, an internationally renowned doctor with over a dozen awards and citations, was felicitated in an event held at the World Trade Center, Cuffe Parade by the Minister of State, Arun Halder. This felicitation came as a recognition of Dr Yuktaka Niihara's work - the development of an FDA-approved drug ENDARI to fight the scrounge of Sickle cell syndrome worldwide. The event was hosted by Dr Aditi Govatrikar, a famous Bollywood personality, and Miss World.

Dr Yukata Niihara felicitated by Minister of State, Arun Halder for developing FDA- approved drug ENDARI to fight SCD | Dr Yukata Niihara felicitated by Minister of State, Arun Halder for developing FDA- approved drug ENDARI to fight SCD

Dr Yukata Niihara felicitated by Minister of State, Arun Halder for developing FDA- approved drug ENDARI to fight SCD

Dr Yukata Niihara, e CEO and Chair of Emmaus life sciences Inc. USA, an internationally renowned doctor with over a dozen awards and citations, was felicitated in an event held at the World Trade Center, Cuffe Parade by the Minister of State, Arun Halder. This felicitation came as a recognition of Dr Yuktaka Niihara's work - the development of an FDA-approved drug ENDARI to fight the scrounge of Sickle cell syndrome worldwide. The event was hosted by Dr Aditi Govatrikar, a famous Bollywood personality, and Miss World.

Over 20 million people in India suffer from sickle cell disease (SCD) due to genetic reasons. Tribal communities, in particular, are affected at a disproportionately high percentage and suffer exorbitantly because of being underprivileged and lack of resources. To ameliorate their condition and save hundreds of lives, it is vitally necessary to introduce this medication in India.

Dr Niihara has tied up with an Indian Mumbai-based company, Akash Biomatrix Pvt. Ltd. represented by the undersigned to market and distribute this medicine in India at affordable prices. Emmaus Life sciences Inc of the USA is also seriously exploring setting up a manufacturing and Biotech research facility in India with an initial investment of over USD 300 million.

This story has been provided by SRV.will not be responsible in any way for the content in this article. (ANI/SRV)

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in app